Skip to main content

HEALTH

  • Generics lift Endo’s 3Q

    CHADDS FORD, Pa. Strong generic sales helped Endo edge analyst expectations for the third quarter, the company noted.

    Net income reached $54.2 million, compared with $49.4 million during the period ended Sept. 30. Net sales jumped 23% to $444.1 million, versus $361 million during the same period a year ago. Analysts had estimated sales of $443.36 million for the quarter.

  • Amgen R&D chief testifies at FDA biosimilar hearing

    THOUSAND OAKS, Calif. Amgen's SVP research and development, Joe Miletich, urged members of a Food and Drug Administration panel to establish approval standards for biosimilars that ensure patient safety and follow a science-based approach.

    “Put patients first and sound policy will follow,” Miletich said. “Amgen believes biosimilars have a meaningful role to play in the healthcare system. However, dissimilar — unlike generic drugs — are not identical to the innovative biological products.” 

  • Brioschi Pharmaceuticals to revitalize Brioschi heartburn-relief brand

    FAIR LAWN, N.J. Brioschi Pharmaceuticals International last month announced its intent to revitalize the Brioschi heartburn-relief brand. The company is pitting substantial capital into a marketing plan that incorporates everything from trade promotions, sampling and healthcare professional recommendations to newspaper advertising, digital marketing and sponsorships, the company stated.

     

  • Prestige Brands completes purchase of Blacksmith Brands

    IRVINGTON, N.Y. Prestige Brands Holdings on Monday announced that it has completed its previously announced purchase of Blacksmith Brands Holdings.

     

    The transaction was finalized under the original terms announced on Sept. 20, which called for Prestige to pay $190 million in cash at closing plus a customary working capital adjustment that amounted to $13.4 million.

     

  • Wegmans introduces co-branded glucose monitoring system with Nipro

    ROCHESTER, N.Y. Wegmans on Monday announced the availability of its co-branded blood-glucose monitoring systems: Nipro Diagnostics’ TrueResult system and True2go.

     

  • Hyland's looks to have reformulated teething tablets back on the market in 2011

    LOS ANGELES Hyland’s plans to have a reformulated Teething Tablets product back on the market in early 2011, the company stated, following the initiation of its voluntary recall of the product last week.

     

  • Research shows retail clinics can replace up to 1-in-4 emergency room visits

    CONSHOHOCKEN, Pa. Up to 1-in-4 emergency room visits could take place at a retail-based health clinic or urgent care center, saving potentially $4.4 billion annually, according to new research published in the September issue of Health Affairs.

    Furthermore, the research found that such retail clinics as Take Care Clinics have been shown to save patients $279 to $460 per visit compared with emergency room costs.

X
This ad will auto-close in 10 seconds